Announcing our newest cancer test. Screen cancer early with Onco-D-clare. Learn more
We’re revolutionizing cancer care through scientific discovery and innovation.
We focus our efforts on providing a range of cancer care options that go beyond traditional chemotherapy.
The complexity of cancer makes personalization vital to cancer treatment. We offer personalized care solutions to improve your outcomes.
Discover the power of our non-invasive CTC blood tests, which provide real-time monitoring of your cancer status using liquid biopsies.
The detection and monitoring of CTC markers circulating in the blood are used for screening, prognosis, and predicting a patient’s response to specific types of therapy.
A patient-centric revolution in cancer testing and monitoring.
We are devoted to providing personalized tests designed with each patient’s unique genetic profile in mind.
We are dedicated to pushing the boundaries of cancer care by:
• Using cutting-edge research
• Revolutionizing cancer testing
• Making precision medicine possible
A pioneer in personalized cancer care.
In 2004, genetics pioneer Dr. Ioannis Papasotiriou founded RGCC with a steadfast commitment to personalized cancer care. Driven by his unwavering belief in the power of a patient’s genes, Dr. Papasotiriou has passionately refused to access external funding that could compromise his vision and commitment to a science-driven cancer solution.
His dedication and expertise have enabled RGCC to stand at the forefront of cancer treatment, providing hope and healing to patients and their families around the world.
Our state-of-the-art testing methodologies provide unique insights into your cancer’s nature and behavior, identifying what makes your cancer diagnosis different from others.
Unprecedented cancer testing and monitoring
At RGCC, we go beyond identifying if you have cancer. We monitor the unique progress of cancer and cancer treatment in your body.
All our accredited practitioners are trained to guide you through the testing options and will make recommendations that are right for you.
The power of our monitoring tests is they give you a measure of whether a treatment option is working or not so you can change course if needed. Along with the Onconomics panels which provide information about personalized treatment options, you have information on options that may be more effective for you.
Each patient is unique. How often you should see your practitioner must be decided in consultation with them after they have reviewed your case. Although this timing may vary based on factors such as treatment options, within our process, monitoring is recommended every 3 months with active cancer to monitor effectiveness of treatments, and every 6-12 months in remission to monitor for early signs of recurrence as part of your Recurrence Prevention Program.
Even when you receive the “all clear” from your Oncologist, there may be CSCs (Circulating Stem Cell-like Cells) also known as TICs (Tumor Initiating Cells) still active and in circulation but at a level below the sensitivity of standard-of-care monitoring tests, such as imaging and physiological cancer marker testing.
This means active cancer cells may be present, but they cannot be detected via traditional means until the cancer has grown big enough to be detected again. This leaves you vulnerable and without treatment because in the standard-of-care model, if you can’t see it, you can’t treat it, enabling the cancer to come back.
TIC monitoring with our OncoTrace and OncoTrail allows you to monitor these cells on a microscopic level allowing you to continue care until these cells are no longer active or if in remission, allowing you to see new activity as soon as it starts.
Cancer is often more aggressive when there is a recurrence. This highlights the importance of having a Recurrence Prevention Program once the cancer has gone into remission or as part of your post-treatment aftercare.
Standard-of-care monitoring tests are not sensitive enough to detect early-stage recurrence activity. This allows cancer to take hold before it is detected, making it harder to treat. If you can’t see it, you can’t treat it.
At RGCC, our OncoCount, OncoTrace, and OncoTrail monitoring tests detect the presence of cancer cells on a microscopic level, allowing for the earliest detection and treatment of recurrence allowing for a proactive, rather than reactive approach to care.
